

Ebola Virus Stability on Surfaces and in Fluids in Simulated Outbreak Environments

Robert Fischer,¹ Seth Judson,¹
Kerri Miazgowicz, Trenton Bushmaker,
Joseph Prescott, Vincent J. Munster

We evaluated the stability of Ebola virus on surfaces and in fluids under simulated environmental conditions for the climate of West Africa and for climate-controlled hospitals. This virus remains viable for a longer duration on surfaces in hospital conditions than in African conditions and in liquid than in dried blood.

Since March 2014, >22,000 cases of Ebola virus disease (EVD) and \approx 9,000 deaths have been reported in West Africa (1). Thousands of health care professionals have been mobilized to West Africa to assist with the ongoing outbreak of EVD (2). More than 800 Ebola virus (EBOV) infections have been reported in health care professionals (1).

Determining the persistence of EBOV on surfaces and under environmental conditions specific to outbreak settings and disease-endemic areas is critical to improving safety practices for these health care workers (3), as well as answering questions about EBOV transmission among the public (4). Researchers have experimentally assessed the stability of other EBOV strains on plastic, glass, and steel within dried media or guinea pig serum (5); in the dark on glass (6); and during exposure to UV light (7). However, the environmental conditions of these studies do not reflect the higher temperatures and relative humidities (RHs) in outbreak regions, or the current outbreak strain. No infectious EBOV could be found during environmental sampling in a ward with EVD patients; however, this result could be more indicative of cleaning measures than actual virus stability (8).

We report stability of EBOV with a current outbreak strain from Guinea (Makona-WPGC07) (9) on 3 clinically relevant surfaces: stainless steel, plastic, and Tyvek (Dupont, Wilmington, DE, USA). We also determined the stability of EBOV in water, spiked human blood, and blood from infected nonhuman primates (NHPs). These experiments were conducted in 2 environmental conditions, 21°C, 40% RH, and 27°C, 80% RH, to simulate a climate-controlled hospital and the environment in West Africa, respectively.

The Study

We tested the stability of EBOV on 3 materials commonly found in an Ebola treatment unit (ETU) in West Africa: 1) utility-grade (308) stainless steel washers (McMaster-Carr, Atlanta, GA, USA); 2) plastic (Teflon [polytetrafluoroethylene]; McMaster-Carr); and 3) Tyvek (from the front of a coverall). For each time point, 3 disks (4-cm diameter) of each material were placed individually into wells of a 6-well plate. Five samples (10 μ L/sample) containing a total dose of 10^6 50% tissue culture infectious doses (TCID₅₀s) of EBOV in cell-free medium were evenly distributed on the disks. The plates were divided into groups, and each group was placed into a plastic HEPA-filtered box and placed at 21°C, 40% RH, or 27°C, 80% RH. The samples were dried naturally, and virus titers were determined over a 14-day period.

In the surface and fluid stability experiments, all samples were stored at -80°C until titration (1 freeze-thaw cycle of EBOV samples that did not change virus titer). Titrations were performed on Vero E6 cells as described (10,11). The TCID₅₀ per milliliter for each sample at each time point was calculated by using the Spearman-Kärber method (11).

Because viral decay rates often exhibit first-order kinetics (12), we \log_{10} transformed our TCID₅₀ calculations to represent virus titer and used a linear regression analysis (Prism version 6.05; GraphPad, San Diego, CA, USA) to determine the \log_{10} reduction rate of EBOV on each surface at both environmental conditions (Figure 1; Table 1). We also determined whether linear regression models were significantly different from each other at the $p < 0.05$ level by using an analysis of covariance equivalent test in Prism. Overall, virus remained viable longest in hospital conditions and on Tyvek. Viable EBOV was detectable for 3 days on Tyvek at tropical conditions.

The stability of EBOV in water was assessed by diluting 150 μ L virus stock in 2.85 mL of Ambion diethylpyrocabonate-treated water (Thermo Fisher Scientific, Pittsburgh, PA, USA) and removing residual protein and medium with 1 initial and 2 rinse spins on Amicon Ultra Centrifugal Filters 100K MWCO (Merck, Darmstadt, Germany). EBOV was more stable in water at 21°C and had an $\approx 1 \log_{10}$ reduction/day in water at 27°C (Table 1; Figure 2, panel A).

The stability of EBOV in human blood was assessed by spiking blood samples from a healthy human volunteer

Author affiliation: National Institutes of Health, Hamilton, Montana, USA

DOI: <http://dx.doi.org/10.3201/eid2107.150253>

¹These authors contributed equally to this article.




Figure 2. Linear regression model showing stability of Ebola virus (EBOV) in fluids under different environmental conditions. A) EBOV stability in water at 2 environmental temperatures. Virus concentration was reduced at a significantly faster rate in 27°C water than in 21°C water ($p = 0.0001$). B) Stability in drying or liquid EBOV-spiked human blood samples at 2 environmental conditions. Virus concentration was reduced at a significantly faster rate by drying than in liquid blood at both conditions ($p < 0.0001$ for each condition). No significant difference between reduction rates in virus titer in drying human blood at both conditions was found ($p = 0.92$). Triplicate samples were taken at each time point. Error bars indicate mean \pm SEM virus titer. Dashed line indicates the limit of detection for the assay. An analysis of covariance equivalent test was used to compare linear regression models and determine differences in virus reduction rates. TCID₅₀, 50% tissue culture infectious dose.

EBOV maintained viability for a longer duration in liquid than in drying blood regardless of initial titer or environmental condition.

Conclusions

We found that EBOV can persist on surfaces common in an ETU, highlighting the need for adherence to thorough disinfection and doffing protocols when exiting the ETUs and careful handling of medical waste. In addition, EBOV maintains viability for a longer duration in liquid than in dried blood. EBOV in blood of experimentally infected NHPs persists for a similar duration as EBOV in spiked human blood. A recent study showed that blood in the body

cavity of an NHP contained viable EBOV for up to 7 days after death (13). We detected viable EBOV in drying blood for up to 5 days at both environmental conditions in human and NHP blood. Therefore, dried and liquid blood from an infected person in their home or ETU should be treated as potentially infectious. The finding that EBOV remains viable in water for as long as 3 (27°C) or 6 (21°C) days at the experimental concentration warrants further investigation into the persistence of the virus in aqueous environments, such as in wastewater or sewage canals. Viable EBOV has been isolated from urine (14) but not from human stool (8). Therefore, the potential for dissemination of EBOV through wastewater remains unknown.

This study is subject to several limitations. First, because standard volumes for samples were used, different volumes or matrices could influence the stability of EBOV under the tested conditions. Second, blood samples from the NHPs might have different immunologic or biochemical conditions, which can potentially influence virus stability. Third, the experimental conditions in the laboratory are sterile, but in disease-endemic areas and ETUs, bacteria or chemicals could influence EBOV viability.

Overall, we found that different environmental conditions, fluids, and surfaces influence the persistence of EBOV. These findings demonstrate that such factors are crucial in understanding transmission and improving safety practices.

This study was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Table 2. Stability of Ebola virus in infected nonhuman primate blood under different environmental conditions*

Blood sample, condition	Initial virus titer, log ₁₀ TCID ₅₀ /mL	No. days viable
NHP 1		
Drying 27°C, RH 80%	6.5	5
Drying 21°C, RH 40%	6.5	1
Liquid 27°C	7.2	14
Liquid 21°C	7.2	14
NHP 2		
Drying 27°C, RH 80%	2.8	5
Drying 21°C, RH 40%	2.8	1
Liquid 27°C	4.2	11
Liquid 21°C	4.2	1
NHP 3		
Drying 27°C, RH 80%	7.2	4
Drying 21°C, RH 40%	7.2	4
Liquid 27°C	6.5	8
Liquid 21°C	6.5	14

*TCID₅₀, 50% tissue culture infectious dose; NHP, nonhuman primate; RH, relative humidity.




Figure 2. Linear regression model showing stability of Ebola virus (EBOV) in fluids under different environmental conditions. A) EBOV stability in water at 2 environmental temperatures. Virus concentration was reduced at a significantly faster rate in 27°C water than in 21°C water ($p = 0.0001$). B) Stability in drying or liquid EBOV-spiked human blood samples at 2 environmental conditions. Virus concentration was reduced at a significantly faster rate by drying than in liquid blood at both conditions ($p < 0.0001$ for each condition). No significant difference between reduction rates in virus titer in drying human blood at both conditions was found ($p = 0.92$). Triplicate samples were taken at each time point. Error bars indicate mean \pm SEM virus titer. Dashed line indicates the limit of detection for the assay. An analysis of covariance equivalent test was used to compare linear regression models and determine differences in virus reduction rates. TCID₅₀, 50% tissue culture infectious dose.

EBOV maintained viability for a longer duration in liquid than in drying blood regardless of initial titer or environmental condition.

Conclusions

We found that EBOV can persist on surfaces common in an ETU, highlighting the need for adherence to thorough disinfection and doffing protocols when exiting the ETUs and careful handling of medical waste. In addition, EBOV maintains viability for a longer duration in liquid than in dried blood. EBOV in blood of experimentally infected NHPs persists for a similar duration as EBOV in spiked human blood. A recent study showed that blood in the body

cavity of an NHP contained viable EBOV for up to 7 days after death (13). We detected viable EBOV in drying blood for up to 5 days at both environmental conditions in human and NHP blood. Therefore, dried and liquid blood from an infected person in their home or ETU should be treated as potentially infectious. The finding that EBOV remains viable in water for as long as 3 (27°C) or 6 (21°C) days at the experimental concentration warrants further investigation into the persistence of the virus in aqueous environments, such as in wastewater or sewage canals. Viable EBOV has been isolated from urine (14) but not from human stool (8). Therefore, the potential for dissemination of EBOV through wastewater remains unknown.

This study is subject to several limitations. First, because standard volumes for samples were used, different volumes or matrices could influence the stability of EBOV under the tested conditions. Second, blood samples from the NHPs might have different immunologic or biochemical conditions, which can potentially influence virus stability. Third, the experimental conditions in the laboratory are sterile, but in disease-endemic areas and ETUs, bacteria or chemicals could influence EBOV viability.

Overall, we found that different environmental conditions, fluids, and surfaces influence the persistence of EBOV. These findings demonstrate that such factors are crucial in understanding transmission and improving safety practices.

This study was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Table 2. Stability of Ebola virus in infected nonhuman primate blood under different environmental conditions*

Blood sample, condition	Initial virus titer, log ₁₀ TCID ₅₀ /mL	No. days viable
NHP 1		
Drying 27°C, RH 80%	6.5	5
Drying 21°C, RH 40%	6.5	1
Liquid 27°C	7.2	14
Liquid 21°C	7.2	14
NHP 2		
Drying 27°C, RH 80%	2.8	5
Drying 21°C, RH 40%	2.8	1
Liquid 27°C	4.2	11
Liquid 21°C	4.2	1
NHP 3		
Drying 27°C, RH 80%	7.2	4
Drying 21°C, RH 40%	7.2	4
Liquid 27°C	6.5	8
Liquid 21°C	6.5	14

*TCID₅₀, 50% tissue culture infectious dose; NHP, nonhuman primate; RH, relative humidity.

Dr. Fischer and Dr. Judson are researchers in the Virus Ecology Unit at Rocky Mountain Laboratories in Hamilton, Montana. Their research interests are the ecology and evolution of emerging infectious diseases and relationships between human and environmental health.

References

1. Ebola situation report WHO—28 January 2015 [cited 2015 Feb 12]. <http://apps.who.int/ebola/en/ebola-situation-report/situation-reports/ebola-situation-report-11-february-2015>
2. Medecins Sans Frontieres. Ebola crisis update³ 3th January 2015 [cited 2015 Feb 12]. <http://www.msf.org/article/ebola-crisis-update-13th-january-2015>
3. Institute of Medicine. Research priorities to inform public health and medical practice for Ebola virus disease: workshop in brief. 2014 [cited 2015 Feb 12]. <http://iom.edu/Reports/2014/Research-Priorities-to-Inform-Public-Health-and-Medical-Practice-for-Ebola-Virus-Disease-WIB.aspx>
4. Judson S, Prescott J, Munster V. Understanding Ebola virus transmission. *Viruses*. 2015;7:511–21. <http://dx.doi.org/10.3390/v7020511>
5. Piercy TJ, Smither SJ, Steward JA, Eastaugh L, Lever MS. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. *J Appl Microbiol*. 2010;109:1531–9.
6. Sagripanti JL, Rom AM, Holland LE. Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. *Arch Virol*. 2010;155:2035–9. <http://dx.doi.org/10.1007/s00705-010-0791-0>
7. Sagripanti JL, Lytle CD. Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces. *Arch Virol*. 2011;156:489–94. <http://dx.doi.org/10.1007/s00705-010-0847-1>
8. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. *J Infect Dis*. 2007;196(Suppl 2):S142–7. <http://dx.doi.org/10.1086/520545>
9. Hoenen T, Groseth A, Feldmann F, Marzi A, Ebihara H, Kobinger G, et al. Complete genome sequences of three Ebola virus isolates from the 2014 outbreak in west Africa. *Genome Announc*. 2014;2:e01331-14. <http://dx.doi.org/10.1128/genomeA.01331-14>
10. van Doremalen N, Bushmaker T, Munster VJ. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. *Euro Surveill*. 2013;18:pii/20599.
11. Hierholzer J, Killington R. Virus isolation and quantitation. In: Mahy B, Kangro H, editors. *Virology methods manual*. London: Academic Press; 1996. p. 25–46.
12. Stallknecht DE, Shane S, Kearney M, Zwank P. Persistence of avian influenza viruses in water. *Avian Dis*. 1990;34:406–11. <http://dx.doi.org/10.2307/1591428>
13. Prescott J, Bushmaker T, Fischer R, Miazgowiec K, Judson S, Munster VJ. Postmortem stability of Ebola virus. *Emerg Infect Dis*. 2015;21:856–9. <http://dx.doi.org/10.3201/eid2105.150041>
14. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. *N Engl J Med*. 2014;371:2394–401. <http://dx.doi.org/10.1056/NEJMoa1411677>

Address for correspondence: Vincent Munster, Rocky Mountain Laboratories, 903 South 4th St, Hamilton, MT, USA;
email: vincent.munster@nih.gov



Scan this QR Code with your smartphone and enjoy listening to our podcasts about the latest emerging infectious diseases.

<http://wwwnc.cdc.gov/eid/podcasts.htm>

**EID
PODCAST**
www.cdc.gov/ncidod/EID/podcast/